Premium
O1–02–06: A midlife risk score for the prediction of dementia more than three decades later
Author(s) -
Whitmer Rachel A.,
Barnes Deborah,
Kivipelto Miia,
Quesenberry Charles P.,
Ngandu Tiia,
Yaffe Kristine
Publication year - 2007
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.04.092
Subject(s) - dementia , medicine , framingham risk score , population , gerontology , disease , diabetes mellitus , vascular dementia , hyperlipidemia , physical therapy , environmental health , endocrinology
(MDC/CCL22). MDC was chosen for its ability to target and deliver antigens to professional antigen-presenting cells, and to elicit Th2-type polarized immune responses. Results: We demonstrated that the pMDC3A 1-11-PADRE vaccine induced robust anti-A antibody and Th2 type anti-PADRE T cell responses in 3xTg-AD mouse model. Multiple immunizations of 3-4 mo old mice protected them from age-related behavioral impairment and significantly inhibited development of A plaques. Currently, we further investigate, and will be reporting the quantity of soluble (monomeric/oligomeric) and insoluble forms of A 42/40 peptides as well as phosphorylated tau accumulated in the brains of immune and control animals. Conclusion: Considering our above-mentioned data along with others’ results demonstrating that AD plaques undergo chemical modifications thus making them more resistant to disruption with age while soluble forms of A amyloid are trapped in vasculature in immunized patients, we suggest that anti-A vaccine might be effective as prophylactic, but not therapeutic measure and should be used for vaccination of middle-aged healthy people. However, recent publications demonstrate that A peptide plays an essential role at synapse and in synaptic structurefunctional plasticity. A is shown to mediate a physiological homeostatic mechanism that regulates synaptic activity. Therefore, preventive vaccine should be designed very carefully, and we need to study whether preventive vaccination may have deleterious consequences for patients with mild cognitive impairment, or healthy people. All these issues will be discussed during the presentation.